Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT

Fig. 3

DAS-II GCA scorea by cognitive category in patients starting idursulfase-IT in the A RCTb and B extension study. a Patients without data available for year 2 (week 100 or week 104) are not shown. b Patients who received treatment with idursulfase-IT in the RCT began the extension study during the extended treatment phase, which reflected a reduced frequency of assessments compared with the schedule in the RCT (neurodevelopmental assessments performed every 24 weeks). DAS-II Differential Ability Scales, Second Edition; GCA General Conceptual Ability; IT intrathecal; RCT randomized controlled trial

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172